• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Zagazig Journal of Forensic Medicine and Toxicology
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 23 (2025)
Volume Volume 22 (2024)
Issue Issue 2
Issue Issue 1
Volume Volume 21 (2023)
Volume Volume 20 (2022)
Volume Volume 19 (2021)
Volume Volume 18 (2020)
Volume Volume 17 (2019)
Volume Volume 16 (2018)
Volume Volume 15 (2017)
Volume Volume 14 (2016)
Volume Volume 13 (2015)
Abdelkader, S., Mahmoud, A., Wahdan, M., El morsy, S. (2024). Hydroxychloroquine from Safety to Death: Case Series. Zagazig Journal of Forensic Medicine and Toxicology, 22(1), 19-32. doi: 10.21608/zjfm.2023.223504.1156
Salma Abdelkader; Alaa Essam Mahmoud; Maha Magdy Wahdan; Sarah El morsy. "Hydroxychloroquine from Safety to Death: Case Series". Zagazig Journal of Forensic Medicine and Toxicology, 22, 1, 2024, 19-32. doi: 10.21608/zjfm.2023.223504.1156
Abdelkader, S., Mahmoud, A., Wahdan, M., El morsy, S. (2024). 'Hydroxychloroquine from Safety to Death: Case Series', Zagazig Journal of Forensic Medicine and Toxicology, 22(1), pp. 19-32. doi: 10.21608/zjfm.2023.223504.1156
Abdelkader, S., Mahmoud, A., Wahdan, M., El morsy, S. Hydroxychloroquine from Safety to Death: Case Series. Zagazig Journal of Forensic Medicine and Toxicology, 2024; 22(1): 19-32. doi: 10.21608/zjfm.2023.223504.1156

Hydroxychloroquine from Safety to Death: Case Series

Article 2, Volume 22, Issue 1, January 2024, Page 19-32  XML PDF (1.45 MB)
Document Type: Original Article
DOI: 10.21608/zjfm.2023.223504.1156
View on SCiNiTO View on SCiNiTO
Authors
Salma Abdelkader1; Alaa Essam Mahmoud2; Maha Magdy Wahdanorcid 3; Sarah El morsy email orcid 4
1lecturerForensic medicine and clinical toxicology,faculty of medicine, ainshams unuiversity
2lecturer inForensic medicine and clinical toxicology department, faculty of medicine, ainshams university
3Lecturer in Community Medicine, Environmental, and Occupational Medicine Department - Faculty of Medicine Ain Shams University, Cairo, Egypt.
4Lecturer in Forensic medicine and clinical toxicology department, faculty of medicine, ainshams university
Abstract
Introduction: Hydroxychloroquine (HCQ) has been used to treat many autoimmune diseases. Early in the era of the COVID-19 pandemic, HCQ was an essential arm in its management. Later, updated evidence had recommendations against its use in cases of COVID-19; however, its abundance in homes raised the risk of its misuse.  Aim: This study aimed to describe patients with acute hydroxychloroquine toxicity who presented to the Poison Control Centre Ain Shams at University Hospitals (PCC-ASUH) including the management and the outcomes. Method: Medical records of patients with acute HCQ toxicity presented to PCC-ASUH from the beginning of December 2020 to the end of December 2021 were reviewed. Patients’ demographics, clinical parameters, laboratory investigations, electrocardiography (ECG) findings, treatment were presented and interpreted. Results: Eleven patients of acute HCQ poisoning during the study duration; ten survived, and one died. The most common presenting symptoms were vomiting and hypotension. The ECG abnormalities observed in two patients were wide QRS complexes and prolonged QT intervals. Patients were treated symptomatically. Hypotension was initially treated by intravenous (IV) fluids. Vasopressors were used in three patients. Conclusion: Although the incidence of acute HCQ toxicity is low, it can be fatal. The treatment is based mainly on early IV fluid resuscitation. The vasopressors were added to patients after the failure of fluid therapy. Patients required meticulous ECG and serum electrolytes monitoring, particularly serum Potassium (K) levels. Recommendations: The study recommended the early use of epinephrine as a vasopressor after the failure of IV fluid therapy to correct the hypotension in HCQ-poisoned patients. Intravenous diazepam should be considered with endotracheal intubation (ETT) and mechanical ventilation (MV) in the treatment. 
Keywords
Chloroquine; Hydroxychloroquine; COVID-19 Treatment; SLE; High Dose Diazepam
Statistics
Article View: 275
PDF Download: 360
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.